Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

First regimen to be approved in India to demonstrate superiority to platinum-containing chemotherapy, the current standard of care for adult patients with unresectable or metastatic urothelial cance ...

AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing ...

Nebraska's highest court upheld the denial of workers' compensation death benefits to a widow who claimed her husband's ...

Astellas Pharma India has announced that the Central Drugs Standard Control Organisation (CDSCO) has approved PADCEV ...

Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...

Urothelial carcinoma accounts for the vast majority of bladder cancers and presents along a continuum from non-muscle-invasive lesions to muscle-invasive and metastatic disease. Non-muscle-invasive ...

Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial Among 343 patients analyzed, 217 (63.3%) had ...

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...